EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2013. Scientific Opinion on the substantiation of a health claim related to pantothenic acid and contribution to normal energy-yielding metabolism pursuant to Article 14 of Regulation (EC) No 1924/2006

EFSA Publication; Tetens, Inge

Link to article, DOI: 10.2903/j.efsa.2013.3411

Publication date: 2013

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):

DTU Library
Technical Information Center of Denmark

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
SCIENTIFIC OPINION

Scientific Opinion on the substantiation of a health claim related to pantothenic acid and contribution to normal energy-yielding metabolism pursuant to Article 14 of Regulation (EC) No 1924/2006

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

European Food Safety Authority (EFSA), Parma, Italy

ABSTRACT

Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to pantothenic acid and contribution to normal energy-yielding metabolism. The food constituent, pantothenic acid, which is the subject of the health claim, is sufficiently characterised. Contribution to normal energy-yielding metabolism is a beneficial physiological effect for infants and young children. A claim on pantothenic acid and normal energy-yielding metabolism in the general population has already been assessed with a favourable outcome. The Panel notes that the role of pantothenic acid in normal energy-yielding metabolism applies to all ages, including infants and young children (from birth to three years). The Panel concludes that a cause and effect relationship has been established between the dietary intake of pantothenic acid and contribution to normal energy-yielding metabolism.

© European Food Safety Authority, 2013

KEY WORDS

pantothenic acid, infants, children, energy-yielding metabolism, health claims
SUMMARY

Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to pantothenic acid and contribution to normal energy-yielding metabolism.

The scope of the application was proposed to fall under a health claim referring to children’s development and health.

The food constituent that is the subject of the health claim is pantothenic acid which is an essential nutrient and is measurable in foods by established methods. The Panel considers that pantothenic acid is sufficiently characterised.

The claimed effect proposed by the applicant is “plays an important role in the energy metabolism of food”. The target population proposed by the applicant is infants and young children from birth to three years of age. The Panel considers that contribution to normal energy-yielding metabolism is a beneficial physiological effect for infants and young children.

A claim on pantothenic acid and normal energy-yielding metabolism in the general population has already been assessed with a favourable outcome. The conclusion of the Panel was based on the well-established role of pantothenic acid in energy-yielding metabolism as shown by the evidence provided by consensus opinions/reports from authoritative bodies and reviews.

The Panel notes that the role of pantothenic acid on normal energy-yielding metabolism applies to all ages, including infants and young children (from birth to three years).

The Panel concludes that a cause and effect relationship has been established between the dietary intake of pantothenic acid and contribution to normal energy-yielding metabolism.

The following wording reflects the scientific evidence: “Pantothenic acid contributes to normal energy-yielding metabolism”.

The Panel considers that in order to bear the claim, follow-on formulae should comply with the criteria of composition of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally complete foods for special medical purposes intended for use by infants and nutritionally complete foods for special medical purposes other than those intended for use by infants should comply with the criteria of composition of these foods as laid down in Directive 1999/21/EC; processed cereal-based foods for infants and young children should comply with the criteria of composition of these foods as laid down in Directive 2006/125/EC; other foodstuffs intended for infants and young children should provide at least 15 % of the reference values for nutrition labelling for foods intended for infants and young children as laid down in Directive 2006/141/EC. Such amounts can be easily consumed as part of a balanced diet. The target population is infants and children up to three years. No Tolerable Upper Intake Level has been established for pantothenic acid in this age group.
Pantothenic acid and contribution to normal energy-yielding metabolism

TABLE OF CONTENTS

Abstract ........................................................................................................................................... 1
Summary ........................................................................................................................................ 2
Table of contents ........................................................................................................................... 3
Background ...................................................................................................................................... 4
Terms of reference .......................................................................................................................... 4
EFSA Disclaimer ............................................................................................................................. 4
Information provided by the applicant ............................................................................................. 5
Assessment ....................................................................................................................................... 6
1. Characterisation of the food/constituent ....................................................................................... 6
2. Relevance of the claimed effect to human health .......................................................................... 6
3. Scientific substantiation of the claimed effect ............................................................................. 6
4. Panel’s comments on the proposed wording .............................................................................. 7
5. Conditions and restrictions of use .............................................................................................. 7
Conclusions ..................................................................................................................................... 7
Documentation provided to EFSA ................................................................................................... 8
References ......................................................................................................................................... 8
Abbreviations ................................................................................................................................. 10
BACKGROUND

Regulation (EC) No 1924/2006 harmonises the provisions that relate to nutrition and health claims, and establishes rules governing the Community authorisation of health claims made on foods. As a rule, health claims are prohibited unless they comply with the general and specific requirements of this Regulation, are authorised in accordance with this Regulation, and are included in the lists of authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease risk claims and claims referring to children’s development and health in a Community list of permitted claims.

According to Article 15 of this Regulation, an application for authorisation shall be submitted by the applicant to the national competent authority of a Member State, which will make the application and any supplementary information supplied by the applicant available to the European Food Safety Authority (EFSA).

STEPS TAKEN BY EFSA

- The application was received on 14/02/2008.
- The scope of the application was proposed to fall under a health claim referring to children’s development and health.
- On 26/03/2008, during the validation process of the application, EFSA sent a request to the applicant to provide missing information.
- On 02/07/2013, EFSA received the missing information as submitted by the applicant.
- The scientific evaluation procedure started on 17 July 2013.
- During its meeting on 09/10/2013, the NDA Panel, having evaluated the data submitted, adopted an opinion on the scientific substantiation of a health claim related to pantothenic acid and contribution to normal energy-yielding metabolism.

TERMS OF REFERENCE

EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion on the scientific substantiation of a health claim related to: pantothenic acid and contribution to normal energy-yielding metabolism.

EFSA DISCLAIMER

The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing of pantothenic acid, a positive assessment of its safety, nor a decision on whether pantothenic acid is, or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006.

It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation procedure foreseen in Article 17 of Regulation (EC) No 1924/2006.

---

INFORMATION PROVIDED BY THE APPLICANT

Applicant’s name and address: Specialised Nutrition Europe (formerly IDACE), 9-31 Avenue des Nerviens, 1040 Brussels, Belgium.

Food/constituent as stated by the applicant

According to the applicant, the food constituent for which the claim is made is vitamin B5 (pantothenic acid).

Health relationship as claimed by the applicant

According to the applicant, vitamin B5 plays an important role in the energy metabolism of food. Pantothenic acid is used in the synthesis of coenzyme A (CoA). Symptoms of deficiency are similar to other vitamin B deficiencies. There is impaired energy production, due to low CoA levels, which could cause symptoms of irritability, fatigue, and apathy.

Wording of the health claim as proposed by the applicant

The applicant has proposed the following wording for the health claim: “vitamin B5 (pantothenic acid) is needed to release energy from food”.

As equivalent alternative wordings, the applicant has also proposed: “vitamin B5 (pantothenic acid) is needed for fat metabolism/helps the body to use fats properly”.

Specific conditions of use as proposed by the applicant

According to the applicant, the target population is infants and young children from birth to three years of age.

According to the applicant, the quantity needed to achieve the claimed effect is:

- For follow-on formulae, the content in pantothenic acid should be within the range set in Directive 2006/141/EC.
- For dietary foods for special medical purposes, the content in pantothenic acid should be within the range set in Directive 1999/21/EC.
- For processed cereal-based foods and baby foods, the content in pantothenic acid should be within the range set in Directive 2006/125/EC.
- For processed cereal-based foods and baby foods, the content in pantothenic acid should reach at least 15 % of the Nutrient Reference Values set in Directive 2006/141/EC, i.e. 15 % of 3000 µg (450 µg) per 100 g or 100 ml per serving, as reconstituted.
- For foods intended for infants and young children other than follow-on formulae, processed cereal-based foods and baby foods, the content in pantothenic acid should reach at least 15 % of the Nutrient Reference Values set in Directive 2006/141/EC, i.e. 15 % of 3000 µg (450 µg) per 100 g or 100 ml per serving, as reconstituted.
ASSESSMENT

1. Characterisation of the food/constituent
The food constituent that is the subject of the health claim is pantothenic acid (vitamin B5), which is an essential nutrient and is measurable in foods by established methods.


The Panel considers that the food constituent, pantothenic acid, which is the subject of the health claim, is sufficiently characterised.

2. Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is “plays an important role in the energy metabolism of food”. The target population proposed by the applicant is infants and young children from birth to three years of age.

The Panel considers that contribution to normal energy-yielding metabolism is a beneficial physiological effect for infants and young children.

3. Scientific substantiation of the claimed effect
The applicant performed a literature search in PubMed, which was limited to “humans” and “review”, using “B vitamin [ti]” AND “mitochondrial” AND “metabolism” as search terms, without specifying which period was covered. Two review publications on the role of B vitamins on the mitochondrial function were retrieved through this literature search (Depeint et al., 2006a, b). The applicant also identified some opinions/reports from authoritative bodies as being pertinent to the health claim (IoM, 1998; FAO/WHO, 2001; EVM, 2002; SCF, 2002).

Pantothenic acid is required for the biosynthesis of coenzyme A, a cofactor that carries acyl groups for many enzymatic processes, which include fatty acid and amino acid oxidation, and the citric acid cycle. Thus, pantothenic acid has a central role in carbohydrate, protein and lipid catabolism (Trumbo, 2006).

The Panel has already assessed a claim on pantothenic acid and normal energy-yielding metabolism with a favourable outcome (EFSA NDA Panel, 2009). The target population was the general population.

---


The conclusion of the Panel was based on the well-established role of pantothenic acid in energy-yielding metabolism as shown by the evidence provided by consensus opinions/reports from authoritative bodies and reviews (IoM, 1998; Sadler et al., 1999; FAO/WHO, 2001; EVM, 2002; SCF, 2002).

The Panel notes that the role of pantothenic acid in normal energy-yielding metabolism applies to all ages, including infants and young children (from birth to three years).

The Panel concludes that a cause and effect relationship has been established between the dietary intake of pantothenic acid and contribution to normal energy-yielding metabolism.

4. Panel’s comments on the proposed wording

The Panel considers that the following wording reflects the scientific evidence: “Pantothenic acid contributes to normal energy-yielding metabolism”.

5. Conditions and restrictions of use

The Panel considers that in order to bear the claim:

- follow-on formulae should comply with the criteria of composition of follow-on formulae as laid down in Directive 2006/141/EC;
- nutritionally complete foods for special medical purposes intended for use by infants and nutritionally complete foods for special medical purposes other than those intended for use by infants should comply with the criteria of composition of these foods as laid down in Directive 1999/21/EC;
- processed cereal-based foods for infants and young children should comply with the criteria of composition of these foods as laid down in Directive 2006/125/EC;
- other foodstuffs intended for infants and young children should provide at least 15 % of the reference values for nutrition labelling for foods intended for infants and young children as laid down in Directive 2006/141/EC.

Such amounts can be easily consumed as part of a balanced diet. The target population is infants and children up to three years. No Tolerable Upper Intake Level (UL) has been established for pantothenic acid in this age group.

CONCLUSIONS

On the basis of the data presented, the Panel concludes that:

- The food constituent, pantothenic acid, which is the subject of the health claim, is sufficiently characterised.
- The claimed effect proposed by the applicant is “plays an important role in the energy metabolism of food”. The target population proposed by the applicant is infants and young children from birth to three years of age. Contribution to normal energy-yielding metabolism is a beneficial physiological effect for infants and young children.

---

● A cause and effect relationship has been established between the dietary intake of pantothenic acid and contribution to normal energy-yielding metabolism.

● The following wording reflects the scientific evidence: “Pantothenic acid contributes to normal energy-yielding metabolism”.

● In order to bear the claim, follow-on formulae should comply with the criteria of composition of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally complete foods for special medical purposes intended for use by infants and nutritionally complete foods for special medical purposes other than those intended for use by infants should comply with the criteria of composition of these foods as laid down in Directive 1999/21/EC; processed cereal-based foods for infants and young children should comply with the criteria of composition of these foods as laid down in Directive 2006/125/EC; other foodstuffs intended for infants and young children should provide at least 15 % of the reference values for nutrition labelling for foods intended for infants and young children as laid down in Directive 2006/141/EC. Such amounts can be easily consumed as part of a balanced diet. The target population is infants and children up to three years. No UL has been established for pantothenic acid in this age group.

DOCUMENTATION PROVIDED TO EFSA


REFERENCES


EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2009. Scientific Opinion on the substantiation of health claims related to pantothenic acid and energy-yielding metabolism (ID 56, 59, 60, 64, 171, 172, 208), mental performance (ID 57), maintenance of bone (ID 61), maintenance of teeth (ID 61), maintenance of hair (ID 61), maintenance of skin (ID 61), maintenance of nails (ID 61) and synthesis and metabolism of steroid hormones, vitamin D and some neurotransmitters (ID 181) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2009;7(9):1218, 19 pp. doi:10.2903/j.efsa.2009.1218


SCF (Scientific Committee on Food), 2002. Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Level of pantothenic acid.

ABBREVIATIONS

UL  Tolerable Upper Intake Level